AI collaboration shows success for novel heart failure target
Drug Discovery World
MAY 20, 2024
AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI. This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification.
Let's personalize your content